Literature DB >> 34846565

The effect of prophylactic balloon occlusion in patients with placenta accreta spectrum: a Bayesian network meta-analysis.

Mengjun Dai1, Fangqin Zhang1, Yidan Chen2, Xuebin Zhang3, Kangbo Li4, Guangxin Jin1.   

Abstract

OBJECTIVES: Placenta accreta spectrum (PAS) can induce severe life-threatening obstetric hemorrhage. Herein, we conducted a Bayesian network meta-analysis of previous studies to evaluate the relative benefits of different prophylactic balloon occlusion (PBO) procedures.
METHODS: PubMed, Embase, Cochrane Library, and Web of Science were searched from inception to July 2021. Blood loss volume, blood transfusion volume, and hysterectomy rate were regarded as the primary endpoints. The data were pooled using a Bayesian network and traditional pairwise meta-analysis.
RESULTS: Fifty-nine articles with a total sample size of 5150 patients were included. Compared with no PBO (non-PBO) intervention, PBO of the abdominal aorta (PBOAA, mean difference(MD) - 1.02, 95% credible interval (CrI) - 1.4 to - 0.67), common iliac artery (PBOCIA, MD - 0.84; 95%CrI - 1.36 to - 0.06) and internal iliac artery (PBOIIA, MD - 0.42; 95%CrI - 0.72 to - 0.13) significantly lowered blood loss volume, with PBOAA being more effective than PBOIIA (MD - 0.60; 95%CrI - 1.05 to - 0.17). PBOAA and PBOIIA also significantly decreased blood loss volume (MD - 2.33; 95%CrI - 3.74 to - 0.94, MD - 1.57; 95%CrI - 2.77 to - 0.47 respectively) and hysterectomy rate (OR 0.31; 95%CrI 0.16 to 0.54, OR 0.53; 95%CrI 0.29 to 0.92 respectively). PBOAA has the highest probability of being more effective in reducing the blood loss volume, blood transfusion volume, and hysterectomy rate.
CONCLUSIONS: Performing PBOAA, PBOCIA, or PBOIIA in PAS patients is an effective way to minimize blood loss volume, while PBOAA and PBOIIA also reduce blood transfusion volume and hysterectomy rate. PBOAA is a notably more effective strategy to reduce blood loss volume than PBOIIA. KEY POINTS: • PBOAA, PBOCIA, and PBOIIA procedures can significantly reduce the blood loss volume compared to non-PBO intervention in PAS patients, of which PBOAA was more effective than the PBOIIA procedure. • PBOAA and PBOIIA could significantly reduce the blood transfusion volume and hysterectomy rate in contrast to the non-PBO intervention in patients with PAS. • According to our statistical treatment ranking, PBOAA was statistically superior in reducing blood transfusion volume, blood transfusion volume, and hysterectomy rate than other PBO procedures.
© 2021. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Balloon occlusion; Hysterectomy; Placenta accreta; Postpartum hemorrhage

Mesh:

Year:  2021        PMID: 34846565     DOI: 10.1007/s00330-021-08423-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  2 in total

1.  Comparison of emergency cesarean hysterectomy with and without prophylactic placement of intravascular balloon catheters in patients with placenta accreta spectrum.

Authors:  Youwen Mei; Dan Luo; Sumei Wei; Liming Wang; Xiaoyan Liao; Huaibo Jing; Yonghong Lin; Hu Zhao
Journal:  J Matern Fetal Neonatal Med       Date:  2020-09-20

2.  Association between maternal single-nucleotide polymorphisms in HLA-G gene and risk of preeclampsia.

Authors:  Cui Ma; Yuanyuan Zheng; Xiaowei Liu; Weiyuan Zhang
Journal:  J Matern Fetal Neonatal Med       Date:  2021-12-27
  2 in total
  2 in total

1.  Artificial intelligence on MRI for molecular subtyping of diffuse gliomas: feature comparison, visualization, and correlation between radiomics and deep learning.

Authors:  Zijian Zhou
Journal:  Eur Radiol       Date:  2021-11-26       Impact factor: 5.315

2.  The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.

Authors:  Yidan Chen; Xingfei Lv; Sang Lin; Mohammad Arshad; Mengjun Dai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.